Cargando…

Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study

We evaluated the efficacy and safety of aripiprazole in the treatment of irritability in children and adolescents (6–17 years) with autism spectrum disorder (ASD) in a randomized, double-blind, placebo-controlled 8-week study in Japan. Patients received flexibly dosed aripiprazole (1–15 mg/day) or p...

Descripción completa

Detalles Bibliográficos
Autores principales: Ichikawa, Hironobu, Mikami, Katsunaka, Okada, Takashi, Yamashita, Yushiro, Ishizaki, Yuko, Tomoda, Akemi, Ono, Hiroaki, Usuki, Chiharu, Tadori, Yoshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617873/
https://www.ncbi.nlm.nih.gov/pubmed/28004215
http://dx.doi.org/10.1007/s10578-016-0704-x
_version_ 1783267058647040000
author Ichikawa, Hironobu
Mikami, Katsunaka
Okada, Takashi
Yamashita, Yushiro
Ishizaki, Yuko
Tomoda, Akemi
Ono, Hiroaki
Usuki, Chiharu
Tadori, Yoshihiro
author_facet Ichikawa, Hironobu
Mikami, Katsunaka
Okada, Takashi
Yamashita, Yushiro
Ishizaki, Yuko
Tomoda, Akemi
Ono, Hiroaki
Usuki, Chiharu
Tadori, Yoshihiro
author_sort Ichikawa, Hironobu
collection PubMed
description We evaluated the efficacy and safety of aripiprazole in the treatment of irritability in children and adolescents (6–17 years) with autism spectrum disorder (ASD) in a randomized, double-blind, placebo-controlled 8-week study in Japan. Patients received flexibly dosed aripiprazole (1–15 mg/day) or placebo. Ninety-two patients were randomized to placebo (n = 45) or aripiprazole (n = 47). Aripiprazole produced a significant improvement in the mean parent/caregiver-rated Aberrant Behavior Checklist Japanese Version irritability subscale score relative to placebo from week 3 through week 8. Administration of aripiprazole provided significantly greater improvement in the mean clinician-rated Clinical Global Impression-Improvement scores than placebo from week 2 through week 8. All patients randomized to aripiprazole completed the study, and no serious adverse events were reported. Three patients in placebo group discontinued. Aripiprazole was effective and generally safe and well-tolerated in the treatment of irritability associated with ASD in Japanese children and adolescents.
format Online
Article
Text
id pubmed-5617873
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-56178732017-10-12 Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study Ichikawa, Hironobu Mikami, Katsunaka Okada, Takashi Yamashita, Yushiro Ishizaki, Yuko Tomoda, Akemi Ono, Hiroaki Usuki, Chiharu Tadori, Yoshihiro Child Psychiatry Hum Dev Original Article We evaluated the efficacy and safety of aripiprazole in the treatment of irritability in children and adolescents (6–17 years) with autism spectrum disorder (ASD) in a randomized, double-blind, placebo-controlled 8-week study in Japan. Patients received flexibly dosed aripiprazole (1–15 mg/day) or placebo. Ninety-two patients were randomized to placebo (n = 45) or aripiprazole (n = 47). Aripiprazole produced a significant improvement in the mean parent/caregiver-rated Aberrant Behavior Checklist Japanese Version irritability subscale score relative to placebo from week 3 through week 8. Administration of aripiprazole provided significantly greater improvement in the mean clinician-rated Clinical Global Impression-Improvement scores than placebo from week 2 through week 8. All patients randomized to aripiprazole completed the study, and no serious adverse events were reported. Three patients in placebo group discontinued. Aripiprazole was effective and generally safe and well-tolerated in the treatment of irritability associated with ASD in Japanese children and adolescents. Springer US 2016-12-21 2017 /pmc/articles/PMC5617873/ /pubmed/28004215 http://dx.doi.org/10.1007/s10578-016-0704-x Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Ichikawa, Hironobu
Mikami, Katsunaka
Okada, Takashi
Yamashita, Yushiro
Ishizaki, Yuko
Tomoda, Akemi
Ono, Hiroaki
Usuki, Chiharu
Tadori, Yoshihiro
Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study
title Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study
title_full Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study
title_fullStr Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study
title_full_unstemmed Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study
title_short Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study
title_sort aripiprazole in the treatment of irritability in children and adolescents with autism spectrum disorder in japan: a randomized, double-blind, placebo-controlled study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617873/
https://www.ncbi.nlm.nih.gov/pubmed/28004215
http://dx.doi.org/10.1007/s10578-016-0704-x
work_keys_str_mv AT ichikawahironobu aripiprazoleinthetreatmentofirritabilityinchildrenandadolescentswithautismspectrumdisorderinjapanarandomizeddoubleblindplacebocontrolledstudy
AT mikamikatsunaka aripiprazoleinthetreatmentofirritabilityinchildrenandadolescentswithautismspectrumdisorderinjapanarandomizeddoubleblindplacebocontrolledstudy
AT okadatakashi aripiprazoleinthetreatmentofirritabilityinchildrenandadolescentswithautismspectrumdisorderinjapanarandomizeddoubleblindplacebocontrolledstudy
AT yamashitayushiro aripiprazoleinthetreatmentofirritabilityinchildrenandadolescentswithautismspectrumdisorderinjapanarandomizeddoubleblindplacebocontrolledstudy
AT ishizakiyuko aripiprazoleinthetreatmentofirritabilityinchildrenandadolescentswithautismspectrumdisorderinjapanarandomizeddoubleblindplacebocontrolledstudy
AT tomodaakemi aripiprazoleinthetreatmentofirritabilityinchildrenandadolescentswithautismspectrumdisorderinjapanarandomizeddoubleblindplacebocontrolledstudy
AT onohiroaki aripiprazoleinthetreatmentofirritabilityinchildrenandadolescentswithautismspectrumdisorderinjapanarandomizeddoubleblindplacebocontrolledstudy
AT usukichiharu aripiprazoleinthetreatmentofirritabilityinchildrenandadolescentswithautismspectrumdisorderinjapanarandomizeddoubleblindplacebocontrolledstudy
AT tadoriyoshihiro aripiprazoleinthetreatmentofirritabilityinchildrenandadolescentswithautismspectrumdisorderinjapanarandomizeddoubleblindplacebocontrolledstudy